Terms: = Prostate cancer AND BCL9, LGS, 607, ENSG00000116128, MGC131591 AND Treatment
21 results:
1. Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping.
Warner EW; Van der Eecken K; Murtha AJ; Kwan EM; Herberts C; Sipola J; Ng SWS; Chen XE; Fonseca NM; Ritch E; Schönlau E; Bernales CQ; Donnellan G; Munzur AD; Parekh K; Beja K; Wong A; Verbeke S; Lumen N; Van Dorpe J; De Laere B; Annala M; Vandekerkhove G; Ost P; Wyatt AW
Nat Cancer; 2024 Jan; 5(1):114-130. PubMed ID: 38177459
[TBL] [Abstract] [Full Text] [Related]
2. Investigation of iso-propylchaetominine anticancer activity on apoptosis, cell cycle and Wnt signaling pathway in different cancer models.
Karamad V; Sogutlu F; Ozkaya FC; Shademan B; Ebrahim W; El-Neketi M; Avci CB
Fitoterapia; 2024 Mar; 173():105789. PubMed ID: 38158162
[TBL] [Abstract] [Full Text] [Related]
3. Association of radiotherapy for prostate cancer and second primary colorectal cancer: a US population-based analysis.
Tang W; Zhou LJ; Zhang WQ; Jia YJ; Ge MW; Hu FH; Chen HL
Tech Coloproctol; 2023 Dec; 28(1):14. PubMed ID: 38095784
[TBL] [Abstract] [Full Text] [Related]
4. The role of frailty in modifying physical function and quality of life over time in older men with metastatic castration-resistant prostate cancer.
Kim VS; Yang H; Timilshina N; Breunis H; Emmenegger U; Gregg R; Hansen AR; Tomlinson G; Alibhai SMH
J Geriatr Oncol; 2023 Mar; 14(2):101417. PubMed ID: 36682218
[TBL] [Abstract] [Full Text] [Related]
5. Cost effectiveness of treatment strategies for high risk prostate cancer.
Kowalchuk RO; Kim H; Harmsen WS; Jeans EB; Morris LK; Mullikin TC; Miller RC; Wong WW; Vargas CE; Trifiletti DM; Phillips RM; Choo CR; Davis BJ; Beriwal S; Tendulkar RD; Stish BJ; Breen WG; Waddle MR
Cancer; 2022 Nov; 128(21):3815-3823. PubMed ID: 36070558
[TBL] [Abstract] [Full Text] [Related]
6. Quality assurance-based optimization (QAO): Towards improving patient-specific quality assurance in volumetric modulated arc therapy plans using machine learning.
Wall PDH; Fontenot JD
Phys Med; 2021 Jul; 87():136-143. PubMed ID: 33775567
[TBL] [Abstract] [Full Text] [Related]
7. Longitudinal change of comprehensive lower urinary tract symptoms and various types of urinary incontinence during robot-assisted radical prostatectomy.
Fujimura T; Igawa Y; Aizawa N; Niimi A; Yamada Y; Sugihara T; Kamei J; Sato Y; Matsunaga A; Yoshida M; Shinoda Y; Fukuhara H; Nakagawa T; Homma Y; Kume H
Neurourol Urodyn; 2019 Apr; 38(4):1067-1075. PubMed ID: 30995359
[TBL] [Abstract] [Full Text] [Related]
8. miR‑27b‑3p and miR‑607 cooperatively regulate BLM gene expression by directly targeting the 3'‑UTR in PC3 cells.
Chen Y; Zhao J; Duan Z; Gong T; Chen W; Wang S; Xu H
Mol Med Rep; 2019 Jun; 19(6):4819-4831. PubMed ID: 30957187
[TBL] [Abstract] [Full Text] [Related]
9. Multi‑layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/β‑catenin signaling activation (Review).
Katoh M
Int J Mol Med; 2018 Aug; 42(2):713-725. PubMed ID: 29786110
[TBL] [Abstract] [Full Text] [Related]
10. Association of Warfarin Use With Lower Overall cancer Incidence Among Patients Older Than 50 Years.
Haaland GS; Falk RS; Straume O; Lorens JB
JAMA Intern Med; 2017 Dec; 177(12):1774-1780. PubMed ID: 29114736
[TBL] [Abstract] [Full Text] [Related]
11. Expression and Clinical Significance of SOX9 in Renal Cell Carcinoma, Bladder cancer and Penile cancer.
Wan YP; Xi M; He HC; Wan S; Hua W; Zen ZC; Liu YL; Zhou YL; Mo RJ; Zhuo YJ; Luo HW; Jiang FN; Zhong WD
Oncol Res Treat; 2017; 40(1-2):15-20. PubMed ID: 28118628
[TBL] [Abstract] [Full Text] [Related]
12. Immunotherapy for prostate cancer: False promises or true hope?
Rekoske BT; McNeel DG
Cancer; 2016 Dec; 122(23):3598-3607. PubMed ID: 27649312
[TBL] [Abstract] [Full Text] [Related]
13. Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: long-term follow-up of the SPCG-6 study.
Thomsen FB; Brasso K; Christensen IJ; Johansson JE; Angelsen A; Tammela TL; Iversen P;
Eur J Cancer; 2015 Jul; 51(10):1283-92. PubMed ID: 25892647
[TBL] [Abstract] [Full Text] [Related]
14. Deferred permanent prostate seed brachytherapy does not affect PSA outcome: results from a large retrospective cohort.
Chira C; Delouya G; Gruszczynski N; Donath D; Taussky D
Can J Urol; 2013 Dec; 20(6):7028-34. PubMed ID: 24331344
[TBL] [Abstract] [Full Text] [Related]
15. Long-term cancer control after radical prostatectomy and bilateral pelvic lymph node dissection for pT3bN0M0 prostate cancer in the prostate-specific antigen era.
Fairey AS; Daneshmand S; Skinner EC; Schuckman A; Cai J; Lieskovsky G
Urol Oncol; 2014 Feb; 32(2):85-91. PubMed ID: 24183191
[TBL] [Abstract] [Full Text] [Related]
16. Combined intensity-modulated radiation therapy vs. three-dimensional highly conformal radiotherapy after (125)I prostate permanent seed brachytherapy: a comparative treatment planning study.
Zilli T; Boudreau C; Filion EJ; Donath D; Taussky D
Brachytherapy; 2011; 10(5):416-20. PubMed ID: 21316311
[TBL] [Abstract] [Full Text] [Related]
17. Prostatic irradiation is not associated with any measurable increase in the risk of subsequent rectal cancer.
Kendal WS; Eapen L; Macrae R; Malone S; Nicholas G
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):661-8. PubMed ID: 16545920
[TBL] [Abstract] [Full Text] [Related]
18. A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic cancer Group Study No. 6.
Iversen P; Tammela TL; Vaage S; Lukkarinen O; Lodding P; Bull-Njaa T; Viitanen J; Hoisaeter P; Lundmo P; Rasmussen F; Johansson JE; Persson BE; Carroll K;
Eur Urol; 2002 Sep; 42(3):204-11. PubMed ID: 12234503
[TBL] [Abstract] [Full Text] [Related]
19. The impact of race on freedom from prostate-specific antigen failure in prostate cancer patients treated with definitive radiation therapy.
Young CD; Lewis P; Weinberg V; Lee TT; Coleman CW; Roach M
Semin Urol Oncol; 2000 May; 18(2):121-6. PubMed ID: 10875452
[TBL] [Abstract] [Full Text] [Related]
20. Stage T1-2 prostate cancer with pretreatment prostate-specific antigen level < or = 10 ng/ml: radiation therapy or surgery?
Keyser D; Kupelian PA; Zippe CD; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Jul; 38(4):723-9. PubMed ID: 9240638
[TBL] [Abstract] [Full Text] [Related]
[Next]
